AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2022 | $1,030,607 | Replaced |
| 4th Quarter - Amendment (this page) | Oct 26, 2022 | $1,030,607 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW BURNETT New | Legislative Assistant, Office of Sen. Richard Shelby; Health Research and Policy Assistant, Senate Committee on Health, Education, Labor and Pension |
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Medicare/Medicaid MMM
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREW BURNETT New | Legislative Assistant, Office of Sen. Richard Shelby; Health Research and Policy Assistant, Senate Committee on Health, Education, Labor and Pension |
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Budget/Appropriations BUD
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Health Issues HCR
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Disaster Planning/Emergencies DIS
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, physician fee schedule, new test coding and pricing, COVID-19 test coverage and reimbursement, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); regulation and oversight of clinical laboratories, including laboratory developed test services; commercial laboratory surge capacity issues for response to COVID-19 pandemic/epidemic/public health crises. H.R. 6119 - Further Extending Government Funding Act. S.610 - Protecting Medicare and American Farmers from Sequester Cuts Act. S.2209 - VALID Act - To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of in vitro clinical tests, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Insurance INS
COVID-19 test coverage and reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE A KHANI | — |
| THOMAS B SPARKMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.